Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacological Treatments for Acute Respiratory Distress Syndrome

Pharmacological Treatments for Acute Respiratory Distress Syndrome AACN Advanced Critical Care VOLUME 26 � NUMBER 3 � JULY-SEPTEMBER 2015 Volume 26 , Number 3 , pp. 185 - 191 © 2015 AACN Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Pharmacological Treatments for Acute Respiratory Distress Syndrome Melissa Chudow , PharmD Michelle Carter , PharmD Mark Rumbak , MD he term acute respiratory distress syndrome (ARDS) was first coined in 1967 Tto define a clinical syndrome categorized by progressive hypoxemia, dyspnea, and increased work of breathing that is unresponsive to standard respiratory ther- apy. Acute respiratory distress syndrome presents as acute respiratory failure with noncardiogenic pulmonary edema and severe hypoxemia. Historically, this syndrome of potentially fatal pulmonary complications described in critically ill patients was further divided into acute lung injury (ALI) and ARDS, with ALI representing a more mild presentation of ARDS. More recently, the concept of ALI has been replaced with mild, moderate, and severe classifications for ARDS. Despite the substantial progress made in understanding the mechanism of this disease process, ARDS continues to be a major clinical concern. The estimated prevalence in the intensive care unit (ICU) ranges from 4% to 9%, with up to 50% of patients with mild ARDS progressing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png AACN Advanced Critical Care Wolters Kluwer Health

Pharmacological Treatments for Acute Respiratory Distress Syndrome

AACN Advanced Critical Care , Volume 26 (3) – Jul 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/pharmacological-treatments-for-acute-respiratory-distress-syndrome-8HDjfFGZdl

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
© 2015 American Association of Critical-Care Nurses
ISSN
1559-7768
eISSN
1559-7776
DOI
10.1097/NCI.0000000000000092
pmid
26200722
Publisher site
See Article on Publisher Site

Abstract

AACN Advanced Critical Care VOLUME 26 � NUMBER 3 � JULY-SEPTEMBER 2015 Volume 26 , Number 3 , pp. 185 - 191 © 2015 AACN Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Pharmacological Treatments for Acute Respiratory Distress Syndrome Melissa Chudow , PharmD Michelle Carter , PharmD Mark Rumbak , MD he term acute respiratory distress syndrome (ARDS) was first coined in 1967 Tto define a clinical syndrome categorized by progressive hypoxemia, dyspnea, and increased work of breathing that is unresponsive to standard respiratory ther- apy. Acute respiratory distress syndrome presents as acute respiratory failure with noncardiogenic pulmonary edema and severe hypoxemia. Historically, this syndrome of potentially fatal pulmonary complications described in critically ill patients was further divided into acute lung injury (ALI) and ARDS, with ALI representing a more mild presentation of ARDS. More recently, the concept of ALI has been replaced with mild, moderate, and severe classifications for ARDS. Despite the substantial progress made in understanding the mechanism of this disease process, ARDS continues to be a major clinical concern. The estimated prevalence in the intensive care unit (ICU) ranges from 4% to 9%, with up to 50% of patients with mild ARDS progressing

Journal

AACN Advanced Critical CareWolters Kluwer Health

Published: Jul 1, 2015

There are no references for this article.